GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism
Open accessThe DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
Glucagon-like peptide-1 (GLP-1) is an endogenous insulinotropic peptide secreted from the gastrointestinal tract in response to food intake. It enhances pancreatic islet β-cell proliferation and glucose-dependent insulin secretion, and lowers blood glucose and food intake in patients with type 2 diabetes mellitus (T2DM). A long-acting GLP-1 receptor (GLP-1R) agonist, exendin-4 (Ex-4), is the first of this new class of antihyperglycemia drugs approved to treat T2DM. GLP-1Rs are coupled to the cAMP second messenger pathway and, along with pancreatic cells, are expressed within the nervous system of rodents and humans, where receptor activation elicits neurotrophic actions. We detected GLP-1R mRNA expression in both cultured embryonic primary cerebral cortical and ventral mesencephalic (dopaminergic) neurons. These cells are vulnerable to hypoxia- and 6-hydroxydopamine–induced cell death, respectively. We found that GLP-1 and Ex-4 conferred protection in these cells, but not in cells from Glp1r knockout (-/-) mice. Administration of Ex-4 reduced brain damage and improved functional outcome in a transient middle cerebral artery occlusion stroke model. Ex-4 treatment also protected dopaminergic neurons against degeneration, preserved dopamine levels, and improved motor function in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease (PD). Our findings demonstrate that Ex-4 can protect neurons against metabolic and oxidative insults, and they provide preclinical support for the therapeutic potential for Ex-4 in the treatment of stroke and PD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Moreover, GLP-1RAs have demonstrated considerable therapeutic promise in animal models of both PD and AD.427–429”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [427]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition to its effects on metabolic regulation, GLP-1, when synthesized within the brain, exhibits neuroprotective properties.397,427,431”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [427]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“There is increasing evidence from animal studies and clinical trials to suggest that GLP-1 receptor agonists could be beneficial in the treatment of PD, and one study using a prebiotic supplement that enhanced SCFA levels showed an increase GLP-1 levels in mouse models [141–144].”
From The gut–brain axis in early Parkinson’s disease: from prodrome to prevention (2025) · cites this paper as [143]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“There is increasing evidence from animal studies and clinical trials to suggest that GLP-1 receptor agonists could be beneficial in the treatment of PD, and one study using a prebiotic supplement that enhanced SCFA levels showed an increase GLP-1 levels in mouse models [141–144].”
From The gut–brain axis in early Parkinson’s disease: from prodrome to prevention (2025) · cites this paper as [143]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Biology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639 · cited 10×
“These and other actions are mediated through the G protein-coupled GLP-1R, and Ex-4 has demonstrated therapeutic value in T2DM (7).”
BackgroundMethodInfluentialDiabetes mellitus and the risk of dementia: The Rotterdam Study
Ott, A., Stolk, R. P., van Harskamp, F., Pols, H. A. P., Hofman, A., & Breteler, M. M. B. (1999) · Neurology · doi:10.1212/wnl.53.9.1937 · Cited by 2,175
A role for glucagon-like peptide-1 in the central regulation of feeding
Turton, M. D., O'Shea, D., Gunn, I., Beak, S. A., Edwards, C. M. B., Meeran, K., Choi, S. J., Taylor, G. M., Heath, M. M., Lambert, P. D., et al. (1996) · Nature · doi:10.1038/379069a0 · Cited by 1,950 · cited 1×
“GLP-1R mRNA occurs widely throughout the brains of rodents (9) and humans (6,7,10), and both GLP-1 and Ex-4 can readily enter the brain (11) to modify feeding and satiety (12).”
BackgroundJavitch, J. A., D'Amato, R. J., Strittmatter, S. M., & Snyder, S. H. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.7.2173 · Cited by 1,263 · cited 2×
“Administration of MPTP in mice induces a consistent dopaminergic cell loss that parallels many aspects of PD (16,20).”
BackgroundDiabetes mellitus and risk of Alzheimer disease and decline in cognitive function
Arvanitakis, Z., Wilson, R. S., Bienias, J. L., Evans, D. A., & Bennett, D. A. (2004) · Archives of Neurology · doi:10.1001/archneur.61.5.661 · Cited by 1,258 · cited 3×
“Although T2DM now occurs more often in the young, the incidence rises dramatically with age, along with that of many of other conditions, including acute and chronic neurologic disorders, exemplified by stroke (2), Parkinson’s disease (PD) and Alzheimer’s disease (AD) (3,4), which, like T2DM, were once considered rela…”
BackgroundD'Mello, S. R., Galli, C., Ciotti, T., & Calissano, P. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.23.10989 · Cited by 892 · cited 1×
“cAMPmediated pathways are central to the antiapoptotic actions of GLP-1 in -cells (6–8), and the neuroprotective effects of cAMPelevating agents are seen in many neuronal cells, including sensory (24), dopaminergic (25), septal cholinergic (26), cerebellar granule (27,28), and spinal cord motor neurons (29).”
BackgroundGlucagon-like peptide-1 receptor is involved in learning and neuroprotection
During, M. J., Cao, L., Zuzga, D. S., Francis, J. S., Fitzsimons, H. L., Jiao, X., Bland, R. J., Klugmann, M., Banks, W. A., Drucker, D. J., et al. (2003) · Nature Medicine · doi:10.1038/nm919 · Cited by 851 · cited 2×
“These neurotrophic/protective actions are in accordance with previous findings establishing that GLP-1R stimulation protects hippocampal neurons from amyloid- peptide–, Fe2 -, and glutamate-induced toxicity (15,32,33).”
BackgroundResultInsulin and neurodegenerative disease: shared and specific mechanisms
Craft, S., & Stennis Watson, G. (2004) · The Lancet Neurology · doi:10.1016/s1474-4422(04)00681-7 · Cited by 830
Mattson, M. P. (2007) · Aging Cell · doi:10.1111/j.1474-9726.2007.00275.x · Cited by 751 · cited 2×
“Evidence for classic apoptosis in both conditions includes elevated levels of the apoptotic stress-activated protein kinases, caspase-3 (19–21) and of proapoptotic genes and proteins (19,21,22), as was evident in our cell culture studies.”
BackgroundSelf-citationCell death in the nervous system
Bredesen, D. E., Rao, R. V., & Mehlen, P. (2006) · Nature · doi:10.1038/nature05293 · Cited by 636 · cited 2×
“Evidence for classic apoptosis in both conditions includes elevated levels of the apoptotic stress-activated protein kinases, caspase-3 (19–21) and of proapoptotic genes and proteins (19,21,22), as was evident in our cell culture studies.”
Background
Research works printed but not linked: 2
- R Sicree, J Shaw, P Zimmet Diabetes Atlas, ed D Gan (International Diabetes Federation, 3rd Ed, Brussels), pp. 15–103 (2006).
- 10.1210/endo.140.3.6550 · doi:10.1210/endo.140.3.6550 · Paper page
Cited by
Items 501–600 of 629
Larsson, M., Patrone, C., von Euler, M., Holst, J. J., & Nathanson, D. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0896-z · Cited by 7
Parkinson’s disease and brain insulin signaling: Mechanisms and potential role of GLP-1 mimetics
Foroozanmehr, B., Hemmati, M. A., Yaribeygi, H., Karav, S., Jamialahmadi, T., & Sahebkar, A. (2025) · Brain Research · doi:10.1016/j.brainres.2025.149738 · Cited by 6
Zhang, Y., Lv, Y., Yang, T., Liu, Q., & Guo, Q. (2025) · Journal of Alzheimer s Disease Reports · doi:10.1177/25424823251361056 · Cited by 6
“99,100 IR is associated with an increased risk of T2DM and impaired fasting glucose in AD, and the duration of T2DM correlates with the density of brain amyloid plaques, suggesting a shared pathological mechanism involving amyloid aggregation in both diseases.”
Xu, Y., Chen, L., & Zhang, J. (2025) · Journal of Health Population and Nutrition · doi:10.1186/s41043-025-01052-5 · Cited by 6
“It has been verified that Glucagon-like peptide-1 receptor agonists (GLP-1RAs) can markedly diminish the likelihood of ischemic stroke in patients suffering from type 2 diabetes mellitus [48].”
Nanocarriers to mediate the pathways from diabetes toward Parkinson's disease
De, S., & Kuo, Y. (2024) · Journal of the Taiwan Institute of Chemical Engineers · doi:10.1016/j.jtice.2024.105401 · Cited by 6
Incretin Mimetics as Potential Disease Modifying Treatment for Alzheimer’s Disease
Crook, H., & Edison, P. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-240730 · Cited by 6
Inflammation: Role in Parkinson's Disease and Target for Therapy
Flood, P. M., Arbabzada, N., & Sharma, M. (2016) · InTech eBooks · doi:10.5772/63164 · Cited by 6
“Exena‐ tide is a synthetic agonist for the GLP‐1 receptor and shows significant promise as neuropro‐ tective in PD animal models [123].”
BackgroundPlummer, M. P., Meier, J. J., & Deane, A. M. (2013) · Critical Care · doi:10.1186/cc12758 · Cited by 6
“Furthermore, preliminary animal data indicate that GLP-1 has neuroprotective eff ects, and pretreatment with a GLP-1 agonist administered intra ventricularly reduced infarct size by 50% in a rodent model of stroke [10].”
BackgroundThe relevance of Asteraceae family plants in most of the neuropsychiatric disorders treatment
Guenné, S., Balmuș, I.-M., Hilou, A., Nabèrè, O., Kiendrébeogo, M., Ciobica, A. S., Lefter, R. M., Poroch, V., & Timofte, D. V. (2016) · International Journal of Phytomedicine · Cited by 6
Insulin signalling: new target for Parkinson's treatments?
Poewe, W. H., & Seppi, K. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32101-3 · Cited by 6
Hanna, A., Connelly, K. A., Josse, R. G., & McIntyre, R. S. (2014) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.2015.972370 · Cited by 6
“In animal models, GLP-1 has been shown to reduce levels of amyloid-beta peptides and protect against oxidative stress [56,59].”
BackgroundDrug discovery and development for Parkinson’s disease: are preclinical models good enough?
Reinares-Sebastián, A., Esteban-García, N., Takada, M., & Trigo‐Damas, I. (2025) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2025.1692592 · Cited by 5
Cui, H., Li, Z., Sun, H., Zhao, W., Ma, H., Li, H., Zhang, Z., Hölscher, C., Ma, D., & Zhang, Z. (2025) · Reviews in the Neurosciences · doi:10.1515/revneuro-2024-0142 · Cited by 5
Drugs and Endogenous Factors as Protagonists in Neurogenic Stimulation
Chiareli, R. A., Marques, B. L., Carvalho, G. A., Souza, R. T. V., Santana, P. H. G., Santiago, H. C., Pinto, M. C. X., Birbrair, A., Parreira, R. C., Ulrich, H., et al. (2022) · Stem Cell Reviews and Reports · doi:10.1007/s12015-022-10423-y · Cited by 5
Lee, C. H., Yoo, K., Ryu, P. D., Park, J. H., Choi, J. H., Kim, S., Hwang, I. K., Kim, Y., & Won, M. (2010) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-010-9632-7 · Cited by 5
“Many studies have showed the physiological roles of GLP-1 and GLP-1R in the brain, such as modulation of neuronal activity, protection against neuronal damage, and regulation of learning and memory processes (Oka et al. 1999; Perry et al. 2002; During et al. 2003; Mattson 2003; Perry et al. 2003; Li et al. 2009 ).”
BackgroundChen, S., Yu, S., Li, Y., Lecca, D., Glotfelty, E. J., Kim, H.-K., Choi, H., Hoffer, B. J., Greig, N. H., Kim, D. S., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-31455-w · Cited by 5
Self-citationHan, W., Dai, S., Sun, X., Liu, S., Zhang, L., & Chen, B. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.178264 · Cited by 4
Brain Ketone Bodies in Health, Evolution and Disease
Bougneres, P. F. (2026) · Cells · doi:10.3390/cells15040382 · Cited by 4
“MCFAs also have the property of stimulating the secretion of glucagon-like peptide-1 (GLP-1) [185,186], which has receptors in the brain [187].”
Samanidou, V., Tsamis, K., Ceasovschih, A., Koufakis, T., Patoulias, D., Rizos, E. C., Rizzo, M., Milionis, H. J., & Barkas, F. (2026) · Journal of Central Nervous System Disease · doi:10.1177/11795735261444425 · Cited by 4
“44 Subsequent studies using systemic routes reported neuroprotection with intravenous administration of Ex-4 in transient focal ischemia, with effects observed when administered at onset or within one hour, and diminished efficacy when delayed beyond a few hours in some models.”
Advanced gene therapy in Parkinson’s disease through innovations in drug delivery systems
Nguyen, P.-A. T., Nguyen, T.-V., & Park, S. (2025) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-025-00739-5 · Cited by 4
“The agonists are peptide chains consisting of approximately 32–44 amino acids that protect TH, leading to improved dopamine production in the midbrain (Li et al. 2009; Yu et al. 2020).”
White, A. C., Krout, I. N., Mouhi, S., Blackmer‐Raynolds, L., Chang, J., Kelly, S. D., Caudle, W. M., & Sampson, T. R. (2025) · Toxicological Sciences · doi:10.1093/toxsci/kfaf076 · Cited by 4
“In addition, emerging experimental and clinical data implicate GLP-1 signaling in limiting PD pathologies (Harkavyi et al. 2008; Li et al. 2009; Aksoy et al. 2017; Athauda et al. 2017; Meissner et al. 2024).”
Novel and experimental therapeutics for the management of motor and non-motor Parkinsonian symptoms
Ullah, I., Wang, X., & Li, H. (2024) · Neurological Sciences · doi:10.1007/s10072-023-07278-7 · Cited by 4
“In MPTP-induced animals, exenatide therapy almost completely restored dopaminergic neurons and motor function [216, 217].”
Semaglutide to remodel mitochondrial dynamics and mitophagy balance for vascular dementia therapy
Yang, X., Feng, P., Zhu, H., Wang, M., Li, N., Bai, B., Sun, Y., Yan, Z., Wei, W., Chang, J., et al. (2025) · View · doi:10.1002/viw.20250013 · Cited by 4
Park, S.-H., & Kim, D. (2015) · Neural Regeneration Research · doi:10.4103/1673-5374.160078 · Cited by 4
“Further, exendin-4 administration protected dopaminergic neurons in MPTP-treated mice (Li et al., 2009).”
BackgroundNanobiotechnology in Parkinson’s Disease
Torres-Ortega, P. V., Martínez-Valbuena, I., Martí‐Andrés, G., Hanafy, A. S., Luquin, M. R., Garbayo, E., & Blanco‐Prieto, M. J. (2019) · Springer eBooks · doi:10.1007/978-3-030-30930-5_7 · Cited by 4
Regenerative Rehabilitation in Sarcopenia, Dynapenia, and Frailty
Baumann, C. W., Clark, B. C., Phillips, B. E., Szewczyk, N. J., & Consitt, L. A. (2022) · Physiology in health and disease · doi:10.1007/978-3-030-95884-8_5 · Cited by 4
Ho, G. J., Takamatsu, Y., Waragai, M., Wada, R., Sugama, S., Takenouchi, T., Fujita, M., Ali, A., Hsieh, M. H.-I., & Hashimoto, M. (2019) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2019.1649141 · Cited by 4
“In a stroke and PD paradigm, Li and colleagues [40] showed that dopaminergic neurons not only express GLP-1 mRNA, but also that GLP-1 protects cultured dopaminergic neurons against 6-hydroxydopamine– induced neuronal loss.”
BackgroundGLP-1R agonists activate human hypothalamic neuronsPreprint
Mazzaferro, S., Chen, H. C., Cahn, O., Yang, A., Shepilov, D., Seah, E., Chen, J., Jawahar, B., Alcaino, C., Macarelli, V., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.04.02.587825 · Cited by 4
“While these findings require validation and mechanistic follow-up, it has not escaped our attention that GLP-1R agonists show neuroprotective and cognitive benefits to mice (During et al. 2003; Li et al. 2009; Panagaki et al. 2018), and humans (Wu et al. 2018; Vadini et al. 2020).”
Effects of GLP-1 receptor agonists on pituitary and adrenal hormones
Heinla, K. (2023) · DSpace repository (University of Tartu) · Cited by 4
Woo, K. A., Jang, Y., Kim, H.-J., & Park, P. J. (2026) · Brain · doi:10.1093/brain/awag130 · Cited by 3
The role of amphipathic and cationic helical peptides in Parkinson's disease
Pintado‐Grima, C., & Ventura, S. (2024) · Protein Science · doi:10.1002/pro.70020 · Cited by 3
Company Profile: Biocompatibles International Plc: Local Drug Delivery for Targeted Therapies
Coppen, D. (2010) · Regenerative Medicine · doi:10.2217/rme.10.5 · Cited by 3
Baran, O., Akgün, M. Y., Kayhan, A., Evran, Ş., Ozbek, A., Akyoldaş, G., Samancı, Y., Demirel, N., Sönmez, D., Serin, H., et al. (2023) · Journal of Cancer Research and Therapeutics · doi:10.4103/jcrt.jcrt_1519_22 · Cited by 3
Waheed, I., Sikandri, T., Zaheen, S., Khakwani, M. M. A. K., An, Z., Liu, T., Zhu, C., & Wei, J. (2025) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.4c00819 · Cited by 3
Implantable Drug Delivery Systems Based on the Principles of Osmosis
Culwell, J. A., Gadea, J. R., Peer, C. E., & Wright, J. C. (2011) · Springer eBooks · doi:10.1007/978-1-4614-0554-2_17 · Cited by 3
“[ 23 ] used ALZET pumps in a mouse model of Parkinson’s disease to demonstrate the neuroprotective effects of exendin-4, a peptide hormone”
MethodLower Gut Hormones and Health Effects Associated with Consumption of Fermentable Fibers
Keenan, M. J., Zhou, J. F., Senevirathene, R., Janes, M. E., & Martin, R. J. (2010) · Wiley eBooks · doi:10.1002/9780470958186.ch4 · Cited by 3
Peptide drugs that have been developed to treat type 2 diabetes show neuroprotective effects
Hölscher, C. (2014) · Regulatory Peptides · doi:10.1016/j.regpep.2014.05.002 · Cited by 3
“In several preclinical studies, this drug has been shown to be neuroprotective in a range of animal models of neurodegenerative diseases, including Alzheimer's and Parkinson's disease [4,5,7].”
Cytoprotective effects of Gymnemic Acid 1 in cellular models of neurodegeneration
Kapse, S. S., & Migliore, M. M. (2025) · Neuropharmacology · doi:10.1016/j.neuropharm.2025.110673 · Cited by 2
Pilśniak, J., Węgrzynek‐Gallina, J., Bednarczyk, B., Buczek, A., Pilśniak, A., Chmiela, T., Jarosińska, A., Siuda, J. S., & Holecki, M. T. (2025) · Life · doi:10.3390/life15121893 · Cited by 2
“Preclinical studies in animal models have demonstrated the neuro-protective and anti-inflammatory properties of GLP-1RAs and confirmed their therapeutic potential for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD) [11–13].”
The challenges of experimental pharmacology in identifying novel treatments for Parkinson's disease
Teil, M., & Huot, P. (2026) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2025.103164 · Cited by 2
Li, Y., Glotfelty, E. J., Parekh, P., Batsaikhan, B., Luo, W., Jackson, S. N., Harvey, B. K., & Greig, N. H. (2026) · Cells · doi:10.3390/cells15141301 · Cited by 2
Self-citationCellular Adaptations to Intermittent Fasting with Emphasis on the Brain
Mattson, M. P. (2024) · Springer eBooks · doi:10.1007/978-3-031-49622-6_7 · Cited by 2
Self-citationCouch Potato: The Antithesis of Hormesis
Mattson, M. P., Stranahan, A. M., & Martin, B. (2009) · Humana Press eBooks · doi:10.1007/978-1-60761-495-1_8 · Cited by 2
Self-citationWang, Y., Sheyner, M., & Yu, S. (2019) · Brain Circulation · doi:10.4103/bc.bc_40_19 · Cited by 2
“This treatment was inspired by their earlier work with a glucagon‑like peptide‑1 agonist exedine‑4 that protected dopaminergic neurons against degeneration, preserved DA levels, and improved motor function in the 1‑methyl‑4‑phenyl‑1,2,3,6‑tetrahydropyridine mouse model of PD.[20] A new formulation of exendin 4 (also n…”
MethodInfluentialSelf-citationBahriz, A., Mansour, M. E.-M., Ibrahim, A., Khalil, D. M., & Elnoury, H. A. (2020) · Benha Medical Journal · doi:10.21608/bmfj.2020.86396 · Cited by 2
Zhou, W., Liu, C., Yu, F., Niu, X., Wang, X., Li, G., & Li, X. (2020) · doi:10.21203/rs.3.rs-26742/v1 · Cited by 2
“The motor function of each mouse was evaluated by counting the number of 429 line crossings during 5 min in the square open-field box, persist for five days [34].”
BackgroundMethodInfluentialVolpato, V., Menassa, D. A., Sheshadri, P., Giussani, S., Rokicki, M., Cardo, L. F., Bafaloukou, M., Schalkamp, A.-K., Zaremba, A., Monzón‐Sandoval, J., et al. (2025) · medRxiv · doi:10.1101/2025.05.28.25328401 · Cited by 2
“Recently, GLP1R agonists used to treat T2D have been proposed as candidate patients 49 .”
Zhou, W., Liu, C., Yu, F., Niu, X., Wang, X., Li, G., & Li, X. (2021) · Research Square · doi:10.21203/rs.3.rs-131164/v1 · Cited by 2
The role of the microtubule manufacturing chaperone TBCD in neuronal development and brain disorders
Rowlands, J. (2021) · eSpace (Curtin University) · Cited by 2
GLP ‐ 1RAs versus metformin and Parkinson's risk in type 2 diabetes
Sun, M., Wang, X., Lu, Z., Yang, Y., Lv, S., Miao, M., Chen, W., Wu, S., & Zhang, J. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70459 · Cited by 1
Alsharif, M., Shrebaty, O., Aloudah, M. A., Alqahtani, M., AlOubili, R. S., Ahmed, M. J., AlBani, B., & Bana, A. E. (2026) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2026.1969490 · Cited by 1
The Role of Central Nervous System Glucagon-Like Peptide-1 in the Regulation of Energy Balance
Barrera, J. G. (2009) · OhioLink ETD Center (Ohio Library and Information Network) · Cited by 1
GLP 1 and Macrovascular Complications
Sleiman, D. (2011) · Journal of Diabetes & Metabolism · doi:10.4172/2155-6156.s4-007 · Cited by 1
“GLP1R are present in the brains of both rodents [39] and humans [40].”
BackgroundResveratrol in pandemic: irritable bowel syndrome and obesity
Paltsyn, A. A., & Sviridkina, N. B. (2021) · Nauchno-prakticheskii zhurnal «Patogenez» · doi:10.25557/2310-0435.2021.03.75-83 · Cited by 1
“GLP-1 продлевает срок жизни мышей при экспериментальных болезнях Хантингтона [17] Альцгеймера [18], Паркинсона и при инсульте [19].”
GLP-1 receptor agonists for Parkinson's disease
Mulvaney, C. A., Duarte, G. S., Menon, S., Handley, J. D., & Emsley, H. C. A. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012990 · Cited by 1
Potential Theraputic Effect of Liraglutide in Male Rats Parkinsonn’Disease Model
Abdulkareem, A. H., Alsaraafb, K. M., Alabbassi, M. G., & Obaidy, M. M. A. (2018) · Al Mustansiriyah Journal of Pharmaceutical Sciences · doi:10.32947/ajps.v17i2.39 · Cited by 1
GABA signaling regulation by GLP-1 receptor agonists and GABA-A receptors modulator
Babateen, O. (2016) · DiVA (Digitala Vetenskapliga Arkivet) · Cited by 1
A Mendelian randomization study of glycemic and anthropometric traits and Parkinson’s diseasePreprint
Grover, S., Graf, R., Klein, C., Brüggemann, N., König, I. R., Fabiola Del Greco, M., & Sharma, M. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.03.31.017566 · Cited by 1
DellaValle, B., Hempel, C., Staalsøe, T., Johansen, F. F., & Kurtzhals, J. A. L. (2016) · Malaria Journal · doi:10.1186/s12936-016-1544-7 · Cited by 1
Zhou, W., Liu, C., Yu, F., Niu, X., Wang, X., Li, G., & Li, X. (2020) · doi:10.21203/rs.3.rs-26742/v2 · Cited by 1
Mitigating neuroinflammation : new potential therapeutics and targets
Glotfelty, E. J. (2023) · Open Archive (Karolinska Institutet) · Cited by 1
Fransson, L. (2014) · Figshare
Development of therapeutics for the treatment of diabetic brain complications
Mansouri, S. (2013) · Figshare
Pleiotropic Effects of an Incretin Hormone
Oh, S. (2013) · Journal of Korean Diabetes · doi:10.4093/jkd.2013.14.3.120
Neurobiological aspects of obesity: dopamine, serotonin, and imaging
van de Giessen, E. (2012) · UvA-DARE (University of Amsterdam)
Molecular regulation of hormone secretion, growth and apoptosis of GLP-1-producing cells
Kappe, C. (2012) · Figshare
Neurotrophin Bdnf and Novel Molecular Targets in Depression
Numakawa, T., Nakajima, S., & Adachi, N. (2013)
Mελέτη των παθοφυσιολογικών μηχανισμών της λαπαροσκοπικής επιμήκους γαστρεκτομής
Papamargaritis, D. (2015) · doi:10.12681/eadd/36095
Effect of GLP-1R Knockout on stroke outcome
Voinea, A. (2014) · DiVA (Digitala Vetenskapliga Arkivet)
Dunbar, M. (2013) · uO Research (University of Ottawa) · doi:10.20381/ruor-3115
Bayliss, J. A. (2017) · Figshare · doi:10.4225/03/58b8c4bc41e03
Exenatide as a novel treatment for Parkinson's Disease
Avilés-Olmos, I. (2013) · UCL Discovery (University College London)
The Role of Glucagon-like Peptides in Experimental Type 1 Diabetes
Hadjiyianni, I. (2010) · TSpace (University of Toronto)
The Acute Regulation of Intestinal Chylomicron Secretion by Glucagon-like Peptides
Hsieh, J. (2012) · TSpace (University of Toronto)
Inflammatory Mechanisms of Depression and Suicidal Behavior
Ventorp, F. (2017) · Lund University Publications (Lund University)
Spielman, L. J. (2017) · cIRcle (University of British Columbia) · doi:10.14288/1.0340695
The effect of L-dopa and neuroprotective agents oncell replacement therapy for Parkinson’s disease.
Elabi, O. F. (2017) · ORCA Online Research @Cardiff (Cardiff University)
Exendin-4 increases extracellular superoxide dismutase expression in cultured astrocytes
Takano, K., komada, Y., kawabe, K., Moriyama, M., & Nakamura, Y. (2017) · Global Drugs and Therapeutics · doi:10.15761/gdt.1000s1001
“In vivo experiments, GLP-1 was reported to protect neurons in rodent models of Alzheimer’s disease (AD) and Parkinson’s disease (PD) [12-14].”
BackgroundHolmes, S. (2018) · Lancaster EPrints (Lancaster University) · doi:10.17635/lancaster/thesis/478
“GLP-1 agonists have also been reported to exhibit neuroprotective abilities in retaliation to hypoxia and oxidative stress, both of which are involved in AD, and to protect the brain against damage in a number of neurological conditions such as stroke and Parkinson’s disease (Li et al., 2009).”
BackgroundGLP-1 receptor agonists for Parkinson's disease (Protocol)
Mulvaney, C. A., Duarte, G. S., Menon, S., Handley, J. D., & Emsley, H. C. A. (2018) · Lancaster EPrints (Lancaster University)
Investigating the mechanisms underlying synaptic and cognitive deficits in alpha-synucleinopathies
Singh, B. (2019) · University of Minnesota Digital Conservancy (University of Minnesota)
Glucagon-like peptide-1 receptor biased agonism and its functional consequences in type 2 diabetes
Jones, B. W. (2017) · Spiral (Imperial College London) · doi:10.25560/65750
Zhang, Q., Zhang, X., & Niu, C.-Y. (2020) · World Chinese Journal of Digestology · doi:10.11569/wcjd.v28.i11.393
Kodamullil, A. T. (2018) · bonndoc (University of Bonn)
Monika (2019) · ERA: Education and Research Archive (University of Alberta) · doi:10.7939/r3-bdqm-y581
Glucagon‐Like Peptide‐1 Receptor Activators
Wagner, M., Evers, A., Bossart, M., & Konkar, A. A. (2021) · Wiley eBooks · doi:10.1002/0471266949.bmc268
Sampedro, J. (2020) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Poewe, W. H., & Mahlknecht, P. (2017) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.727879031.793537429
Kanamarlapudi, V. (2020) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.734616040.793572407
Research Progress on Mechanism of Glucagon-Like Peptide-1 and Aortic Valve Calcification
张, 盼. (2023) · Advances in Clinical Medicine · doi:10.12677/acm.2023.134905
Neuroprotective potential of incretinomimetics
Kokin, A. S., Суплотова, Л. А., Сергеевна, Д. Т., & Makarova, O. B. (2023) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2023-159
New perspectives on the use of glucagon-like peptide 1 in diseases of the central nervous system
Łupina, M., & Listos, J. (2023) · Current Issues in Pharmacy and Medical Sciences · doi:10.2478/cipms-2023-0040
GLP1R Agonists Activate Human POMC NeuronsPreprint
Mazzaferro, S., Chen, H. C., Cahn, O., Yang, A., Shepilov, D., Chen, J., Alcaino, C., Macarelli, V., Mali, I. D., Gribble, F. M., et al. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4855485
藤田, 隼. (2018) · Institutional Repositories DataBase (IRDB) · doi:10.15017/1931849
Dietary Protein and Prebiotic Fiber Improve Energy Balance and Metabolic Health
Singh, A. (2018) · Libraries and Cultural Resources (University of Calgary) · doi:10.11575/prism/32874
Sultan, F. (2022) · Lancaster EPrints (Lancaster University) · doi:10.17635/lancaster/thesis/1559
Clark, M. (2023) · White Rose eTheses Online (University of Leeds, The University of Sheffield, University of York)
Metadata
- Authors
- Li, Y., Perry, T., Kindy, M. S., Harvey, B. K., Tweedie, D., Holloway, H. W., Powers, K., Shen, H., Egan, J. M., Sambamurti, K., Brossi, A., Lahiri, D. K., Mattson, M. P., Hoffer, B. J., Wang, Y., & Greig, N. H.
- Affiliations
- National Institute on Aging (US)
- Medical University of South Carolina (US)
- National Institute on Drug Abuse (US)
- University of North Carolina at Chapel Hill (US)
- Indiana University School of Medicine (US)
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2009-01-27
- Volume
- 106
- Issue
- 4
- Pages
- 1285-1290
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC2633544
- OpenAlex
- W2080785707
- Cited by
- 589
- References
- 45
- Citations by year
- 2026: 18 · 2025: 39 · 2024: 39 · 2023: 24 · 2022: 33 · 2021: 49 · 2020: 41 · 2019: 40 · 2018: 43 · 2017: 34 · 2016: 41 · 2015: 45 · 2014: 34 · 2013: 33 · 2012: 27
- FWCI
- 16.16
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- UNC Libraries
- Funders
- University of Toronto
- National Institutes of Health
- National Institute on Aging
- National Institute on Drug Abuse
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Neuroscience › Neurology › Neuroprotection in Cerebral Ischemia
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- GLP-1 receptor, exendin-4, stroke, Parkinson's disease, dopaminergic neurons, cortical neurons, neuroprotection, MPTP mouse model, middle cerebral artery occlusion, 6-hydroxydopamine, hypoxia, oxidative stress, dopamine levels, motor function
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Exenatide, Animals, Cells, Cultured, Cerebral Cortex, Disease Models, Animal, Dopamine, Embryo, Mammalian, Gene Expression Regulation, Humans, Mesencephalon, Neurons, Parkinson Disease, Peptides, Venoms, 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine, Cell Hypoxia, Treatment Outcome, Cell Death, Receptors, Glucagon, Cytoprotection, Brain Infarction, Stroke, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.